New ICD-10-PCS Codes in

331 codes were added to the 2023 ICD-10-PCS code set, effective October 1, 2022.

Displaying codes 301-331 of 331:

  • XW01348 Introduction of Teclistamab Antineoplastic into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 8
  • XW020D8 Introduction of Engineered Allogeneic Thymus Tissue into Muscle, Open Approach, New Technology Group 8
  • XW03308 Introduction of Spesolimab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 8
  • XW03358 Introduction of Mosunetuzumab Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 8
  • XW03368 Introduction of Afamitresgene Autoleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 8
  • XW03378 Introduction of Tabelecleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 8
  • XW03388 Introduction of Treosulfan into Peripheral Vein, Percutaneous Approach, New Technology Group 8
  • XW03398 Introduction of Inebilizumab-cdon into Peripheral Vein, Percutaneous Approach, New Technology Group 8
  • XW04308 Introduction of Spesolimab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 8
  • XW04358 Introduction of Mosunetuzumab Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 8
  • XW04368 Introduction of Afamitresgene Autoleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 8
  • XW04378 Introduction of Tabelecleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 8
  • XW04388 Introduction of Treosulfan into Central Vein, Percutaneous Approach, New Technology Group 8
  • XW04398 Introduction of Inebilizumab-cdon into Central Vein, Percutaneous Approach, New Technology Group 8
  • XW0DX38 Introduction of Maribavir Anti-infective into Mouth and Pharynx, External Approach, New Technology Group 8
  • XW0G738 Introduction of Maribavir Anti-infective into Upper GI, Via Natural or Artificial Opening, New Technology Group 8
  • XW0H738 Introduction of Maribavir Anti-infective into Lower GI, Via Natural or Artificial Opening, New Technology Group 8
  • XW0H7X8 Introduction of Broad Consortium Microbiota-based Live Biotherapeutic Suspension into Lower GI, Via Natural or Artificial Opening, New Technology Group 8
  • XW133B8 Transfusion of Betibeglogene Autotemcel into Peripheral Vein, Percutaneous Approach, New Technology Group 8
  • XW133C8 Transfusion of Omidubicel into Peripheral Vein, Percutaneous Approach, New Technology Group 8
  • XW133F8 Transfusion of OTL-103 into Peripheral Vein, Percutaneous Approach, New Technology Group 8
  • XW133G8 Transfusion of OTL-200 into Peripheral Vein, Percutaneous Approach, New Technology Group 8
  • XW143B8 Transfusion of Betibeglogene Autotemcel into Central Vein, Percutaneous Approach, New Technology Group 8
  • XW143C8 Transfusion of Omidubicel into Central Vein, Percutaneous Approach, New Technology Group 8
  • XW143F8 Transfusion of OTL-103 into Central Vein, Percutaneous Approach, New Technology Group 8
  • XW143G8 Transfusion of OTL-200 into Central Vein, Percutaneous Approach, New Technology Group 8
  • XXE0X48 Measurement of Brain Electrical Activity, Computer-aided Semiologic Analysis, New Technology Group 8
  • XXE3X58 Measurement of Coronary Artery Flow, Quantitative Flow Ratio Analysis, New Technology Group 8
  • XXE3X68 Measurement of Coronary Artery Flow, Computer-aided Valve Modeling and Notification, New Technology Group 8
  • XXE5X38 Measurement of Infection, Whole Blood Reverse Transcription and Quantitative Real-time Polymerase Chain Reaction, New Technology Group 8
  • XY0YX28 Extracorporeal Introduction of Taurolidine Anti-infective and Heparin Anticoagulant, New Technology Group 8